Bulk of earnings pressure in the first half of 2023, says Citi's Scott Chronert
Teva's generic EpiPen approved in the U.S., with perfect timing - MarketWatch
Teva: Avoid (NYSE:TEVA) | Seeking Alpha
Teva stock drops 10% as generics turnaround looks uncertain - MarketWatch
Well, well,we'll...said he didn't know why “his team” invested which lowered the stock for months then just doubled his… | Dow jones companies, Investing, Dow jones
Declining sales of blockbuster drug drag Teva revenue lower - MarketWatch
Teva Pharmaceutical Names Richard Francis as CEO, President - WSJ
Teva releases generic version of Mylan's EpiPen in limited doses in the U.S. - MarketWatch
Opinion: Multinationals learn the limits of being big - MarketWatch
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Teva Pharmaceutical Is in Recovery - WSJ
Teva beats first-quarter expectations but still has the same old problems - MarketWatch
Is Teva A Falling Drug Company Or A Great Value Proposition (NYSE:TEVA) | Seeking Alpha
Opinion: Multinationals learn the limits of being big - MarketWatch
Teva Pharmaceuticals (@TevaUSA) / Twitter
Drug maker Teva's U.S. unit indicted on price-fixing charges - MarketWatch
Teva Stock Pressured From Antitrust Lawsuit Against Drug Makers | Barron's
Mylan sees opportunity in rival Teva's weakness - MarketWatch
Drugmaker Teva Pharmaceuticals found guilty for contribution to opioid crisis - MarketWatch
MarketWatch on Twitter: "Teva Pharmaceutical named Kare Schultz as its new chief executive https://t.co/pyLR2vL5Ep https://t.co/pD8godrT5C" / Twitter
Teva Stock Sees Another Big Buy From Chairman Sol Barer | Barron's
Teva Stock Soars After Reaching $4.25 Billion Opioid Settlement | Barron's
Perrigo rejects Mylan, opening door for Teva - MarketWatch
Teva to acquire Mexico's Rimsa for $2.3 billion - MarketWatch
